HomeInvestors & MediaNews
- Exhibiting at Booth C11, Hall C, 3F, COEX
April 30, 2025, ABL Bio (CEO Sang Hoon Lee), a company specializing in bispecific antibodies, announced that it will participate in BIO KOREA 2025, which will be held at COEX from May 7th to May 9th.
BIO KOREA marks its 20th anniversary this year as a major biotech event, attended by investors, industry professionals, and researchers. The exhibition program will be held at Hall C, 3rd floor of COEX in Seoul, with ABL Bio’s booth located at C11.
During the event, ABL Bio will present posters highlighting its four key business areas: the Blood-Brain Barrier (BBB) shuttle platform, novel drug candidates, oncology therapeutics, and Antibody-Drug Conjugates (ADC). ABL Bio owns Grabody-B, a BBB shuttle platform aimed at developing treatments for neurodegenerative diseases. On the 7th, the company signed a license agreement with GSK for the Grabody-B platform, which includes an upfront payment and near-term milestones totaling 77.1 million GBP, with the potential deal value reaching up to 2.14 billion GBP, marking the official start of Grabody-B commercialization.
Among ABL Bio’s pipeline, Tovecimig is emerging as a promising drug candidate for second-line treatment of bile duct cancer. Tovecimig is a bispecific antibody targeting VEGF-A (Vascular Endothelial Growth Factor A) and DLL4 (Delta-Like Ligand 4), designed to suppress tumor angiogenesis and induce cancer cell death. In a U.S.-based Phase 2/3 trial conducted by Compass Therapeutics, which holds the global rights to Tovecimig, the drug achieved an Overall Response Rate (ORR) of 17.1% and a Clinical Benefit Rate (CBR) of 61.3% (68/111), meeting the primary endpoint.
In the immuno-oncology field, ABL Bio is developing therapies using its 4-1BB-based bispecific antibody platform, Grabody-T. 4-1BB is a protein involved in activating immune T cells. The lead candidate from this platform, Givastomig, is expected to present Phase 1b topline results this year from a combination trial with nivolumab and chemotherapy.
Moreover, ABL Bio has been accelerating its bispecific ADC development since last year. The company has reinforced its U.S. subsidiary, Neok Bio, by appointing a new CEO and recruiting ADC experts. Clinical trial applications (IND) submissions for the bispecific ADC programs are planned to begin sequentially starting later this year.
Sang Hoon Lee, CEO of ABL Bio said “Through BIO KOREA, we are raising awareness of ABL Bio among domestic and international stakeholders in the bio industry. This year, we aim to highlight our expertise in bispecific antibodies through our booth and poster presentations as well.” He added, “ABL Bio is pursuing sustainable growth centered around four key pillars. We will continue to focus on research and development to deliver good news.”